The main question PROACT 1 aims to answer is whether cardiovascular health improves following polygenic risk-based detection of subclinical coronary atherosclerosis paired with education compared to education alone without knowledge of polygenic risk or subclinical coronary atherosclerosis.~This is a non-randomized controlled trial, which will compare two groups from an existing pool at Mass General Brigham (MGB) that has been screened for eligibility requirements. Middle-aged participants of the MGB Biobank who have high polygenic risk score for coronary artery disease will be compared to matched controls from MGB Primary Care. Both groups will receive the American Heart Association's Life's Essential 8 cardiovascular health education fliers. The MGB Biobank group will additionally receive a high polygenic risk result for coronary artery disease and be invited to participate in a coronary computed tomographic angiography study to identify subclinical coronary artery disease. Change in Life's Essential 8 score from baseline to one-year will be compared.
The goal of this non-randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease and subsequent screening to detect subclinical coronary atherosclerosis on change in cardiovascular health over one year.